FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| wasiiiigton, | D.C. 20049 | |
|--------------|------------|--|
| | | |

| Check this box if no longer subject |
|-------------------------------------|
| to Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | |
|--------------------------|-------|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response | : 0.5 | | | | | | | |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Velleca Mark A. | | | | | 2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [BDTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | | | | | | | | |
|---|--------|---------|--------------------------------------|-----------------|---|---|---|--------------------|---|---|--|-----------------------------|--|--|---|--|--------|-------------------|------------|
| | | | | |] |] | | | | | | | | X | | | | 10% O | |
| (Last) | (Fi | rst) (f | Middle) | | | | | | | | | | | | belov | er (give title v) | | Other (below) | specify |
| C/O BLACK DIAMOND THERAPEUTICS, INC. | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) | | | | | | | | | | | | | |
| ONE MAIN STREET, 14TH FLOOR | | | | 12/1 | I DI I VI DV DD | | | | | | | | | | | | | | |
| | | | | | 4. If A | 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | | pplicable | | | | | | |
| (Street) | | | | | | | | | | | | | | X | Form | filed by On | e Rep | orting Pers | on |
| CAMBR | IDGE M | A 0 | 2142 | | | | | | | | | | | | | filed by Mo | re tha | n One Rep | orting |
| (O:t-) | (0) | -4-) | 7 :\ | | | | | | | | | | | | Perso | on | | | |
| (City) | (S1 | ate) (Z | Zip) | | | | | | | | | | | | | | | | |
| | | Table | I - No | n-Deriva | tive S | Secu | rities | Acq | uired, | Dis | posed of | , or E | Benef | icially | y Own | ed | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da | | | | Execution Date, | | | 3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5) | | | 4 and Securities Beneficially Owned Fol | | ties cially Following | Form (D) o | Ownership orm: Direct of or Indirect (Instr. 4) | 7. Nature of Indirect Beneficial Ownership | | | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) Pri | | ice | Transa | Reported Transaction(s) (Instr. 3 and 4) | | | (Instr. 4) |
| Common Stock 12/16/2 | | | | 2022 | | | A ⁽¹⁾ | | 8,424 | ,424 A \$ | | 1.5(2) | 21,157 | | | D | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) 2. Conversion Date (Month/Day/Year) 2. Conversion Date (Month/Day/Year) 3. Transaction Date Execution Date, if any (Month/Day/Year) | | | ransaction of ode (Instr. Derivative | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | | 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4) | у | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | | |
| | | Code | v | (A) | (D) | Date Exercis | able | Expiration Date | Title | Amou or Numb of Share | er | | | | | | | | |

Explanation of Responses:

- 1. These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
- 2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022.

/s/ Brent Hatzis-Schoch, 12/19/2022 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.